Form 4: Vertex Pharmaceuticals Director Sangeeta N. Bhatia Reports Stock Transactions

Director Sangeeta N. Bhatia reports acquisition of 796 shares of Vertex Pharmaceuticals common stock and disposition of 400 shares under a pre-arranged trading plan.

Summary

• Sangeeta N. Bhatia, a director at Vertex Pharmaceuticals, reported transactions involving the company's common stock.
• On May 1, 2025, Bhatia acquired 796 shares of common stock at a price of $0.
• These shares were acquired as a restricted stock unit award that vests on the first anniversary of the grant date.
• On May 2, 2025, Bhatia disposed of 400 shares of common stock at a price of $505.86 per share.
• This transaction was made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on May 9, 2024.
• Following these transactions, Bhatia beneficially owns 4,831 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is a common practice among publicly traded companies. It provides transparency to investors regarding the trading activities of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in beneficial ownership.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

VRTX, Vertex Pharmaceuticals, Sangeeta N. Bhatia, Form 4, Stock Transaction, Director, Rule 10b5-1, Restricted Stock Units